Santé log

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
Santé log

Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million ...
Santé log

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Santé log

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase ...

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. LifeSci Capital and Citizens ...
Santé log

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Santé log

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor ...
Santé log

The Joint Corp. Signs Asset Purchase Agreement to Sell 22 Corporate Clinics in the Southeast and Delivers Notice to Terminate APA for 45 Clinics in California

Southeast Buyers are Existing Members of the Franchise Community, Further Increasing their Ownership. SCOTTSDALE, Ariz., Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: ...
Santé log

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

(“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 ...
Santé log

FDA Approves the Zenflow Spring® Implant and Delivery System for First-Line Interventional Therapy of Patients with Benign Prostatic Hyperplasia (BPH)

U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring ® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as ...
Santé log

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites. SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc.
Santé log

Oruka Therapeutics Announces New Board Member and Board Transition

As we rapidly advance our co-lead programs through development, I’m pleased to announce this board transition at Oruka,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. “Chris ...
Santé log

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics, where during his 13 years he played a pivotal part in building out their discovery ...